Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 5/20 | 0.74 |
| ▸ | MLNR | O43193 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ME2 | P23368 | 1/20 | 0.40 |
| ▸ | ME1 | P48163 | 1/20 | 0.40 |
| ▸ | ME3 | Q16798 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450181 | 0.87 | LSS (0.56) | LSSMLNRSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6447847 | 0.86 | LSS (0.57) | LSSMLNRSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17358777 | 0.85 | LSS (1.00) | LSSSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6451232 | 0.84 | LSS (0.76) | LSSMLNRSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6446618 | 0.78 | LSS (0.46) | LSSMLNRSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL7141801 | 0.75 | LSS (0.62) | LSS | |
| SCHEMBL27498732 | 0.74 | LSS (0.60) | LSSSMN1; SMN2ALDH1A1L3MBTL1MAPT | |
| SCHEMBL7206605 | 0.73 | LSS (0.50) | LSSSMN1; SMN2ALDH1A1POLBCYP3A4 | |
| SCHEMBL7206600 | 0.73 | LSS (0.50) | LSSSMN1; SMN2ALDH1A1POLBCYP3A4 | |
| SCHEMBL5045773 | 0.73 | LSS (0.61) | LSSALDH1A1POLBL3MBTL1ME2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964974-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | LSS 2/4885MLNR 3309/4885SMN1; SMN2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.